Research
Hormonal
GLP-1 receptor agonists (e.g., semaglutide, tirzepatide) induce significant weight loss (14.9%–20.9%) and improve fertility in obese individuals, particularly those with PCOS, by acting on hypothalamic and brainstem regions to suppress appetite and stimulate GnRH/LH release.
GLP-1 agonists like semaglutide and tirzepatide are highly effective for significant weight loss and can improve fertility in obese individuals, especially those with PCOS. However, they come with high rates of gastrointestinal side effects and weight regain upon discontinuation. They should be used under medical supervision, with careful attention to dosing and long-term management strategies.
GoodSupportsHIGH confidence
At their highest dosages semaglutide and tirzepatide induce 14.9% and 20.9% weight loss respectively... GLP-1 can directly activate the firing of GnRH neurons in mice... GLP-1R agonists can improve fertility... used successfully to improve fertility in some forms of obesity (i.e., obesity associated with polycystic ovarian syndrome)
Source
Food and the brain: Neural and endocrine control of feeding, metabolism, and reproduction
Naira da Silva Mansano et al. · Journal of Neuroendocrinology · 2025
DOI 10.1111/jne.70104
narrative_reviewCited 1×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Leptin acts as a critical signal linking nutritional status to puberty onset and reproductive function in females, with sufficient levels required to activate hypothalamic pathways for ovulation.Good
- Ghrelin, the only gastrointestinal hormone that increases appetite, stimulates dopamine release in the VTA to increase food motivation and sex motivation in males, but reduces sex motivation in females during lactation.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →